An analysis of TNFɑ-inhibitor-treated patients with inflammatory bowel disease (IBD) in the French National Health Insurance database also showed a higher rate of lymphoma (HR 2.41, 95% CI 1.60–3.64) compared with patients with IBD who had no TNF inhibitor exposure (Lemaitre et al., 2017). The gene discussed is TNF; the disease is lymphoma.